June 12 – 17, 2022
Snake envenomation entails more than 5 million people bitten yearly, out of whom 100,000 died and more than 300,000 are permanently disabled. This prompted the World Health Organization to classify snake envenoming as a neglected tropical disease in 2017.
In North Africa, we have more than 400.000 cases of envenomation with 50 deaths per year. These numbers are underestimated with the Cerastes cerastes (Cc) and Macrovipera mauretanica (Mm)are the most medically important snake species.
To this day, the only medication for snake envenomation is immunotherapy. The lack of a specific antivenom against Cc and Mm venoms in North Africa, prompted us to develop two monospecific Fab'2 antivenoms in collaboration with the Butantan Institute in Brazil: one is produced against Moroccan Cc venom and the other against Moroccan Mm.
While we determiated the paraspecific cross-reactivity of the antivenoms developped, the in vitro paraspecifity study surprisingly revealed a cross reactivity between the two monospecific Fab'2 antivenoms developped towards Mm and Cc venoms
venoms from Morocco, Algeria and Tunisia
Please click Download on the upper right corner to see the full abstract.
Naoual Oukkache, José Marcelino, and Abderrahmane Maaroufi, "Development of two monovalent antivenoms against two Moroccan viper venoms– daboia Mauritanica and Cerastes Cerastes" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/75